Rein Therapeutics, Inc. Net Income Loss

• Rein Therapeutics, Inc. showed an increase of +20.7% in Net Income Loss from 2024 to 2025.
• This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: -$3.93 million | Q2 2016: -$5.53 million | Q3 2016: -$4.22 million | Q4 2016: -$4.44 million | Q1 2017: -$4.56 million | Q2 2017: -$4.92 million | Q3 2017: -$6.26 million | Q4 2017: -$6.87 million | Q1 2018: -$7.59 million | Q2 2018: -$9.49 million | Q3 2018: -$7.43 million | Q4 2018: -$7.03 million | Q1 2019: -$7.21 million | Q2 2019: -$7.17 million | Q3 2019: -$7.75 million | Q4 2019: -$7.24 million | Q1 2020: -$6.75 million | Q2 2020: -$4.39 million | Q3 2020: -$5.02 million | Q4 2020: -$4.93 million | Q1 2021: -$6.98 million | Q2 2021: -$5.69 million | Q3 2021: -$6.70 million | Q1 2022: -$8.42 million | Q2 2022: -$7.99 million | Q3 2022: -$6.37 million | Q1 2023: -$4.78 million | Q2 2023: -$1.79 million | Q3 2023: -$1.83 million | Q1 2024: -$7.11 million | Q2 2024: -$8.94 million | Q3 2024: -$5.85 million | Q1 2025: -$5.50 million | Q2 2025: -$6.82 million | Q3 2025: -$5.58 million.
• Over the full 11 years of available data (2015 to 2025), Rein Therapeutics, Inc.'s Net Income Loss has declined by 287.3%.
• Historical annual values: Fiscal year 2025: -$49.87 million | Fiscal year 2024: -$62.88 million | Fiscal year 2023: -$15.73 million | Fiscal year 2022: -$27.33 million | Fiscal year 2021: -$26.16 million | Fiscal year 2020: -$27.33 million | Fiscal year 2019: -$29.37 million | Fiscal year 2018: -$31.55 million | Fiscal year 2017: -$22.60 million | Fiscal year 2016: -$18.12 million | Fiscal year 2015: -$12.88 million.
• Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: August 10, 2026